nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—CYP3A4—Estropipate—osteoporosis	0.0616	0.181	CbGbCtD
Olopatadine—CYP3A4—Calcitriol—osteoporosis	0.0616	0.181	CbGbCtD
Olopatadine—CYP3A4—Ergocalciferol—osteoporosis	0.0492	0.145	CbGbCtD
Olopatadine—CYP3A4—Raloxifene—osteoporosis	0.0411	0.121	CbGbCtD
Olopatadine—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0397	0.117	CbGbCtD
Olopatadine—CYP3A4—Cholecalciferol—osteoporosis	0.0317	0.0934	CbGbCtD
Olopatadine—CYP3A4—Conjugated Estrogens—osteoporosis	0.0291	0.0858	CbGbCtD
Olopatadine—CYP3A4—Estradiol—osteoporosis	0.0256	0.0753	CbGbCtD
Olopatadine—S100B—vertebral column—osteoporosis	0.0165	0.876	CbGeAlD
Olopatadine—S100A13—Estriol—Estropipate—osteoporosis	0.00365	0.328	CbGdCrCtD
Olopatadine—S100A13—Estriol—Conjugated Estrogens—osteoporosis	0.00276	0.249	CbGdCrCtD
Olopatadine—S100A13—Estriol—Estradiol—osteoporosis	0.00238	0.214	CbGdCrCtD
Olopatadine—S100A12—bone marrow—osteoporosis	0.00234	0.124	CbGeAlD
Olopatadine—S100A13—Estriol—Ethinyl Estradiol—osteoporosis	0.00232	0.209	CbGdCrCtD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—IL6R—osteoporosis	0.00114	0.00554	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—KL—osteoporosis	0.00109	0.0053	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—AGER—osteoporosis	0.00108	0.00528	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—AGER—osteoporosis	0.00108	0.00525	CbGpPWpGaD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—IL6R—osteoporosis	0.00108	0.00524	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—IL6R—osteoporosis	0.00103	0.00501	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6R—osteoporosis	0.00102	0.00496	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—AGER—osteoporosis	0.00102	0.00496	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—IL6R—osteoporosis	0.001	0.00487	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—IL6R—osteoporosis	0.000973	0.00474	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—IL6R—osteoporosis	0.000966	0.0047	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6R—osteoporosis	0.000964	0.00469	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—AGER—osteoporosis	0.00096	0.00467	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—IL6R—osteoporosis	0.00095	0.00462	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—IL6R—osteoporosis	0.000947	0.00461	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—IL6R—osteoporosis	0.000914	0.00445	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—IL6R—osteoporosis	0.000911	0.00444	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—AGER—osteoporosis	0.000908	0.00442	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—IL6R—osteoporosis	0.000898	0.00437	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—IL6R—osteoporosis	0.000862	0.00419	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—IL6R—osteoporosis	0.00082	0.00399	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—IL6R—osteoporosis	0.000775	0.00377	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—IL6R—osteoporosis	0.000771	0.00375	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IRAK3—osteoporosis	0.000768	0.00374	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—IRS2—osteoporosis	0.000746	0.00363	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—IL6R—osteoporosis	0.000729	0.00355	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IRAK3—osteoporosis	0.000726	0.00354	CbGpPWpGaD
Olopatadine—Infestation NOS—Estradiol—osteoporosis	0.000721	0.0017	CcSEcCtD
Olopatadine—Infestation—Estradiol—osteoporosis	0.000721	0.0017	CcSEcCtD
Olopatadine—Pain—Raloxifene—osteoporosis	0.00072	0.00169	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00072	0.00169	CcSEcCtD
Olopatadine—Depression—Estradiol—osteoporosis	0.000719	0.00169	CcSEcCtD
Olopatadine—Fatigue—Ibandronate—osteoporosis	0.000719	0.00169	CcSEcCtD
Olopatadine—Dysgeusia—Zoledronate—osteoporosis	0.000716	0.00168	CcSEcCtD
Olopatadine—Pain—Ibandronate—osteoporosis	0.000713	0.00168	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000712	0.00167	CcSEcCtD
Olopatadine—Pruritus—Etidronic acid—osteoporosis	0.000711	0.00167	CcSEcCtD
Olopatadine—Gastrointestinal pain—Estropipate—osteoporosis	0.000711	0.00167	CcSEcCtD
Olopatadine—Back pain—Zoledronate—osteoporosis	0.000707	0.00166	CcSEcCtD
Olopatadine—Feeling abnormal—Alendronate—osteoporosis	0.000706	0.00166	CcSEcCtD
Olopatadine—Oedema—Ethinyl Estradiol—osteoporosis	0.000705	0.00166	CcSEcCtD
Olopatadine—Erythema—Conjugated Estrogens—osteoporosis	0.000704	0.00166	CcSEcCtD
Olopatadine—Muscle spasms—Zoledronate—osteoporosis	0.000703	0.00165	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—ACTG1—osteoporosis	0.000703	0.00342	CbGpPWpGaD
Olopatadine—Dry mouth—Risedronate—osteoporosis	0.000701	0.00165	CcSEcCtD
Olopatadine—Conjunctivitis—Estradiol—osteoporosis	0.000701	0.00165	CcSEcCtD
Olopatadine—Urinary tract infection—Estradiol—osteoporosis	0.000701	0.00165	CcSEcCtD
Olopatadine—Gastrointestinal pain—Alendronate—osteoporosis	0.0007	0.00165	CcSEcCtD
Olopatadine—Infection—Ethinyl Estradiol—osteoporosis	0.0007	0.00165	CcSEcCtD
Olopatadine—Cough—Pamidronate—osteoporosis	0.000698	0.00164	CcSEcCtD
Olopatadine—Pain—Calcitriol—osteoporosis	0.000698	0.00164	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—ESR1—osteoporosis	0.000697	0.00339	CbGpPWpGaD
Olopatadine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000691	0.00163	CcSEcCtD
Olopatadine—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000689	0.00162	CcSEcCtD
Olopatadine—Vision blurred—Zoledronate—osteoporosis	0.000689	0.00162	CcSEcCtD
Olopatadine—Gastrointestinal pain—Raloxifene—osteoporosis	0.000689	0.00162	CcSEcCtD
Olopatadine—Diarrhoea—Etidronic acid—osteoporosis	0.000688	0.00162	CcSEcCtD
Olopatadine—Abdominal pain—Estropipate—osteoporosis	0.000687	0.00162	CcSEcCtD
Olopatadine—Body temperature increased—Estropipate—osteoporosis	0.000687	0.00162	CcSEcCtD
Olopatadine—Feeling abnormal—Ibandronate—osteoporosis	0.000687	0.00162	CcSEcCtD
Olopatadine—S100A12—Toll-Like Receptors Cascades—IL6R—osteoporosis	0.000687	0.00334	CbGpPWpGaD
Olopatadine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000685	0.00161	CcSEcCtD
Olopatadine—Infection—Risedronate—osteoporosis	0.000683	0.00161	CcSEcCtD
Olopatadine—Gastrointestinal pain—Ibandronate—osteoporosis	0.000682	0.0016	CcSEcCtD
Olopatadine—Back pain—Conjugated Estrogens—osteoporosis	0.000681	0.0016	CcSEcCtD
Olopatadine—Epistaxis—Estradiol—osteoporosis	0.00068	0.0016	CcSEcCtD
Olopatadine—Ill-defined disorder—Zoledronate—osteoporosis	0.000678	0.0016	CcSEcCtD
Olopatadine—Body temperature increased—Alendronate—osteoporosis	0.000677	0.00159	CcSEcCtD
Olopatadine—Abdominal pain—Alendronate—osteoporosis	0.000677	0.00159	CcSEcCtD
Olopatadine—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000677	0.00159	CcSEcCtD
Olopatadine—Sinusitis—Estradiol—osteoporosis	0.000676	0.00159	CcSEcCtD
Olopatadine—Nervous system disorder—Risedronate—osteoporosis	0.000674	0.00159	CcSEcCtD
Olopatadine—Discomfort—Pamidronate—osteoporosis	0.000673	0.00158	CcSEcCtD
Olopatadine—Skin disorder—Risedronate—osteoporosis	0.000667	0.00157	CcSEcCtD
Olopatadine—Gastrointestinal pain—Calcitriol—osteoporosis	0.000667	0.00157	CcSEcCtD
Olopatadine—Body temperature increased—Raloxifene—osteoporosis	0.000666	0.00157	CcSEcCtD
Olopatadine—Abdominal pain—Raloxifene—osteoporosis	0.000666	0.00157	CcSEcCtD
Olopatadine—S100B—Innate Immune System—ACTG1—osteoporosis	0.000664	0.00323	CbGpPWpGaD
Olopatadine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000663	0.00156	CcSEcCtD
Olopatadine—Malaise—Zoledronate—osteoporosis	0.000659	0.00155	CcSEcCtD
Olopatadine—Abdominal pain—Ibandronate—osteoporosis	0.000659	0.00155	CcSEcCtD
Olopatadine—Body temperature increased—Ibandronate—osteoporosis	0.000659	0.00155	CcSEcCtD
Olopatadine—Oedema—Pamidronate—osteoporosis	0.000653	0.00154	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—IRS1—osteoporosis	0.000651	0.00317	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—IL6R—osteoporosis	0.000649	0.00316	CbGpPWpGaD
Olopatadine—Infection—Pamidronate—osteoporosis	0.000649	0.00153	CcSEcCtD
Olopatadine—Rhinitis—Estradiol—osteoporosis	0.000649	0.00153	CcSEcCtD
Olopatadine—Abdominal pain—Calcitriol—osteoporosis	0.000645	0.00152	CcSEcCtD
Olopatadine—Body temperature increased—Calcitriol—osteoporosis	0.000645	0.00152	CcSEcCtD
Olopatadine—Hypoaesthesia—Estradiol—osteoporosis	0.000644	0.00152	CcSEcCtD
Olopatadine—Pharyngitis—Estradiol—osteoporosis	0.000642	0.00151	CcSEcCtD
Olopatadine—Hypersensitivity—Estropipate—osteoporosis	0.000641	0.00151	CcSEcCtD
Olopatadine—Nervous system disorder—Pamidronate—osteoporosis	0.000641	0.00151	CcSEcCtD
Olopatadine—Vomiting—Etidronic acid—osteoporosis	0.000639	0.0015	CcSEcCtD
Olopatadine—Cough—Zoledronate—osteoporosis	0.000638	0.0015	CcSEcCtD
Olopatadine—Rash—Etidronic acid—osteoporosis	0.000634	0.00149	CcSEcCtD
Olopatadine—Dermatitis—Etidronic acid—osteoporosis	0.000633	0.00149	CcSEcCtD
Olopatadine—Hypersensitivity—Alendronate—osteoporosis	0.000631	0.00148	CcSEcCtD
Olopatadine—Headache—Etidronic acid—osteoporosis	0.00063	0.00148	CcSEcCtD
Olopatadine—Asthenia—Estropipate—osteoporosis	0.000624	0.00147	CcSEcCtD
Olopatadine—Visual impairment—Estradiol—osteoporosis	0.000624	0.00147	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000618	0.00145	CcSEcCtD
Olopatadine—Pruritus—Estropipate—osteoporosis	0.000615	0.00145	CcSEcCtD
Olopatadine—Discomfort—Zoledronate—osteoporosis	0.000615	0.00145	CcSEcCtD
Olopatadine—Asthenia—Alendronate—osteoporosis	0.000614	0.00145	CcSEcCtD
Olopatadine—Hypersensitivity—Ibandronate—osteoporosis	0.000614	0.00145	CcSEcCtD
Olopatadine—Cough—Conjugated Estrogens—osteoporosis	0.000614	0.00145	CcSEcCtD
Olopatadine—Dyspnoea—Risedronate—osteoporosis	0.000613	0.00144	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—IL6R—osteoporosis	0.000611	0.00298	CbGpPWpGaD
Olopatadine—Dry mouth—Zoledronate—osteoporosis	0.000609	0.00143	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000608	0.00143	CcSEcCtD
Olopatadine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000608	0.00143	CcSEcCtD
Olopatadine—Pruritus—Alendronate—osteoporosis	0.000606	0.00143	CcSEcCtD
Olopatadine—Eye disorder—Estradiol—osteoporosis	0.000605	0.00142	CcSEcCtD
Olopatadine—Hypersensitivity—Calcitriol—osteoporosis	0.000601	0.00141	CcSEcCtD
Olopatadine—Asthenia—Ibandronate—osteoporosis	0.000598	0.00141	CcSEcCtD
Olopatadine—Nausea—Etidronic acid—osteoporosis	0.000597	0.0014	CcSEcCtD
Olopatadine—Oedema—Zoledronate—osteoporosis	0.000597	0.0014	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000595	0.0014	CcSEcCtD
Olopatadine—Diarrhoea—Estropipate—osteoporosis	0.000595	0.0014	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000593	0.0014	CcSEcCtD
Olopatadine—Infection—Zoledronate—osteoporosis	0.000593	0.00139	CcSEcCtD
Olopatadine—Fatigue—Risedronate—osteoporosis	0.000592	0.00139	CcSEcCtD
Olopatadine—Pruritus—Ibandronate—osteoporosis	0.00059	0.00139	CcSEcCtD
Olopatadine—HRH1—G alpha (q) signalling events—MGLL—osteoporosis	0.000588	0.00286	CbGpPWpGaD
Olopatadine—Pain—Risedronate—osteoporosis	0.000588	0.00138	CcSEcCtD
Olopatadine—Diarrhoea—Alendronate—osteoporosis	0.000586	0.00138	CcSEcCtD
Olopatadine—Asthenia—Calcitriol—osteoporosis	0.000586	0.00138	CcSEcCtD
Olopatadine—Nervous system disorder—Zoledronate—osteoporosis	0.000585	0.00138	CcSEcCtD
Olopatadine—Immune system disorder—Estradiol—osteoporosis	0.000585	0.00138	CcSEcCtD
Olopatadine—Mediastinal disorder—Estradiol—osteoporosis	0.000583	0.00137	CcSEcCtD
Olopatadine—Dyspnoea—Pamidronate—osteoporosis	0.000582	0.00137	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CTSK—osteoporosis	0.000582	0.00283	CbGpPWpGaD
Olopatadine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000581	0.00137	CcSEcCtD
Olopatadine—Somnolence—Pamidronate—osteoporosis	0.000581	0.00137	CcSEcCtD
Olopatadine—Skin disorder—Zoledronate—osteoporosis	0.00058	0.00136	CcSEcCtD
Olopatadine—Pruritus—Calcitriol—osteoporosis	0.000577	0.00136	CcSEcCtD
Olopatadine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000576	0.00136	CcSEcCtD
Olopatadine—Diarrhoea—Raloxifene—osteoporosis	0.000576	0.00136	CcSEcCtD
Olopatadine—Dizziness—Estropipate—osteoporosis	0.000575	0.00135	CcSEcCtD
Olopatadine—Oedema—Conjugated Estrogens—osteoporosis	0.000574	0.00135	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—NFATC1—osteoporosis	0.000573	0.00279	CbGpPWpGaD
Olopatadine—Infection—Conjugated Estrogens—osteoporosis	0.000571	0.00134	CcSEcCtD
Olopatadine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000571	0.00278	CbGpPWpGaD
Olopatadine—Diarrhoea—Ibandronate—osteoporosis	0.00057	0.00134	CcSEcCtD
Olopatadine—Dizziness—Alendronate—osteoporosis	0.000566	0.00133	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000564	0.00133	CcSEcCtD
Olopatadine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000563	0.00133	CcSEcCtD
Olopatadine—Erythema—Estradiol—osteoporosis	0.000563	0.00133	CcSEcCtD
Olopatadine—Fatigue—Pamidronate—osteoporosis	0.000563	0.00133	CcSEcCtD
Olopatadine—Gastrointestinal pain—Risedronate—osteoporosis	0.000562	0.00132	CcSEcCtD
Olopatadine—Pain—Pamidronate—osteoporosis	0.000559	0.00131	CcSEcCtD
Olopatadine—Diarrhoea—Calcitriol—osteoporosis	0.000558	0.00131	CcSEcCtD
Olopatadine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000558	0.00131	CcSEcCtD
Olopatadine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000557	0.00131	CcSEcCtD
Olopatadine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000557	0.00131	CcSEcCtD
Olopatadine—Dizziness—Raloxifene—osteoporosis	0.000557	0.00131	CcSEcCtD
Olopatadine—Vomiting—Estropipate—osteoporosis	0.000553	0.0013	CcSEcCtD
Olopatadine—Dysgeusia—Estradiol—osteoporosis	0.000552	0.0013	CcSEcCtD
Olopatadine—Dizziness—Ibandronate—osteoporosis	0.000551	0.0013	CcSEcCtD
Olopatadine—S100B—Innate Immune System—CTSK—osteoporosis	0.000551	0.00268	CbGpPWpGaD
Olopatadine—Rash—Estropipate—osteoporosis	0.000548	0.00129	CcSEcCtD
Olopatadine—Dermatitis—Estropipate—osteoporosis	0.000548	0.00129	CcSEcCtD
Olopatadine—Back pain—Estradiol—osteoporosis	0.000545	0.00128	CcSEcCtD
Olopatadine—Headache—Estropipate—osteoporosis	0.000545	0.00128	CcSEcCtD
Olopatadine—Vomiting—Alendronate—osteoporosis	0.000544	0.00128	CcSEcCtD
Olopatadine—Body temperature increased—Risedronate—osteoporosis	0.000543	0.00128	CcSEcCtD
Olopatadine—Abdominal pain—Risedronate—osteoporosis	0.000543	0.00128	CcSEcCtD
Olopatadine—Muscle spasms—Estradiol—osteoporosis	0.000542	0.00127	CcSEcCtD
Olopatadine—S100B—Innate Immune System—NFATC1—osteoporosis	0.000542	0.00264	CbGpPWpGaD
Olopatadine—Rash—Alendronate—osteoporosis	0.00054	0.00127	CcSEcCtD
Olopatadine—Dermatitis—Alendronate—osteoporosis	0.000539	0.00127	CcSEcCtD
Olopatadine—Feeling abnormal—Pamidronate—osteoporosis	0.000538	0.00127	CcSEcCtD
Olopatadine—Headache—Alendronate—osteoporosis	0.000536	0.00126	CcSEcCtD
Olopatadine—Vomiting—Raloxifene—osteoporosis	0.000535	0.00126	CcSEcCtD
Olopatadine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000534	0.00126	CcSEcCtD
Olopatadine—Dyspnoea—Zoledronate—osteoporosis	0.000532	0.00125	CcSEcCtD
Olopatadine—Rash—Raloxifene—osteoporosis	0.000531	0.00125	CcSEcCtD
Olopatadine—Dermatitis—Raloxifene—osteoporosis	0.000531	0.00125	CcSEcCtD
Olopatadine—Somnolence—Zoledronate—osteoporosis	0.00053	0.00125	CcSEcCtD
Olopatadine—Vomiting—Ibandronate—osteoporosis	0.00053	0.00125	CcSEcCtD
Olopatadine—Headache—Raloxifene—osteoporosis	0.000528	0.00124	CcSEcCtD
Olopatadine—Rash—Ibandronate—osteoporosis	0.000526	0.00124	CcSEcCtD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.000526	0.00256	CbGpPWpGaD
Olopatadine—Dermatitis—Ibandronate—osteoporosis	0.000525	0.00124	CcSEcCtD
Olopatadine—Ill-defined disorder—Estradiol—osteoporosis	0.000523	0.00123	CcSEcCtD
Olopatadine—Headache—Ibandronate—osteoporosis	0.000522	0.00123	CcSEcCtD
Olopatadine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000519	0.00122	CcSEcCtD
Olopatadine—Vomiting—Calcitriol—osteoporosis	0.000519	0.00122	CcSEcCtD
Olopatadine—Nausea—Estropipate—osteoporosis	0.000516	0.00122	CcSEcCtD
Olopatadine—Abdominal pain—Pamidronate—osteoporosis	0.000516	0.00121	CcSEcCtD
Olopatadine—Body temperature increased—Pamidronate—osteoporosis	0.000516	0.00121	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000515	0.00121	CcSEcCtD
Olopatadine—Rash—Calcitriol—osteoporosis	0.000515	0.00121	CcSEcCtD
Olopatadine—Fatigue—Zoledronate—osteoporosis	0.000514	0.00121	CcSEcCtD
Olopatadine—Dermatitis—Calcitriol—osteoporosis	0.000514	0.00121	CcSEcCtD
Olopatadine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000512	0.00121	CcSEcCtD
Olopatadine—Headache—Calcitriol—osteoporosis	0.000511	0.0012	CcSEcCtD
Olopatadine—Somnolence—Conjugated Estrogens—osteoporosis	0.000511	0.0012	CcSEcCtD
Olopatadine—Pain—Zoledronate—osteoporosis	0.00051	0.0012	CcSEcCtD
Olopatadine—Nausea—Alendronate—osteoporosis	0.000509	0.0012	CcSEcCtD
Olopatadine—Malaise—Estradiol—osteoporosis	0.000508	0.0012	CcSEcCtD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—osteoporosis	0.000507	0.00247	CbGpPWpGaD
Olopatadine—Hypersensitivity—Risedronate—osteoporosis	0.000506	0.00119	CcSEcCtD
Olopatadine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000506	0.00119	CcSEcCtD
Olopatadine—Nausea—Raloxifene—osteoporosis	0.0005	0.00118	CcSEcCtD
Olopatadine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000499	0.00117	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000496	0.00117	CcSEcCtD
Olopatadine—Fatigue—Conjugated Estrogens—osteoporosis	0.000495	0.00117	CcSEcCtD
Olopatadine—Nausea—Ibandronate—osteoporosis	0.000495	0.00117	CcSEcCtD
Olopatadine—Asthenia—Risedronate—osteoporosis	0.000493	0.00116	CcSEcCtD
Olopatadine—Feeling abnormal—Zoledronate—osteoporosis	0.000492	0.00116	CcSEcCtD
Olopatadine—Cough—Estradiol—osteoporosis	0.000492	0.00116	CcSEcCtD
Olopatadine—Pain—Conjugated Estrogens—osteoporosis	0.000491	0.00116	CcSEcCtD
Olopatadine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000488	0.00115	CcSEcCtD
Olopatadine—Pruritus—Risedronate—osteoporosis	0.000486	0.00114	CcSEcCtD
Olopatadine—Nausea—Calcitriol—osteoporosis	0.000485	0.00114	CcSEcCtD
Olopatadine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000482	0.00113	CcSEcCtD
Olopatadine—Hypersensitivity—Pamidronate—osteoporosis	0.000481	0.00113	CcSEcCtD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—osteoporosis	0.000479	0.00233	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—IRS2—osteoporosis	0.000477	0.00232	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000476	0.00112	CcSEcCtD
Olopatadine—Discomfort—Estradiol—osteoporosis	0.000474	0.00112	CcSEcCtD
Olopatadine—Body temperature increased—Zoledronate—osteoporosis	0.000472	0.00111	CcSEcCtD
Olopatadine—Abdominal pain—Zoledronate—osteoporosis	0.000472	0.00111	CcSEcCtD
Olopatadine—Diarrhoea—Risedronate—osteoporosis	0.00047	0.00111	CcSEcCtD
Olopatadine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00047	0.00111	CcSEcCtD
Olopatadine—Dry mouth—Estradiol—osteoporosis	0.000469	0.0011	CcSEcCtD
Olopatadine—Asthenia—Pamidronate—osteoporosis	0.000469	0.0011	CcSEcCtD
Olopatadine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000466	0.0011	CcSEcCtD
Olopatadine—Pruritus—Pamidronate—osteoporosis	0.000462	0.00109	CcSEcCtD
Olopatadine—Oedema—Estradiol—osteoporosis	0.00046	0.00108	CcSEcCtD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—IL6—osteoporosis	0.000459	0.00223	CbGpPWpGaD
Olopatadine—Infection—Estradiol—osteoporosis	0.000457	0.00107	CcSEcCtD
Olopatadine—Dizziness—Risedronate—osteoporosis	0.000454	0.00107	CcSEcCtD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—osteoporosis	0.000454	0.00221	CbGpPWpGaD
Olopatadine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000454	0.00107	CcSEcCtD
Olopatadine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000454	0.00107	CcSEcCtD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000453	0.00221	CbGpPWpGaD
Olopatadine—Nervous system disorder—Estradiol—osteoporosis	0.000451	0.00106	CcSEcCtD
Olopatadine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000448	0.00105	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—SOST—osteoporosis	0.000448	0.00218	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IRAK3—osteoporosis	0.000447	0.00218	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000447	0.00218	CbGpPWpGaD
Olopatadine—Diarrhoea—Pamidronate—osteoporosis	0.000447	0.00105	CcSEcCtD
Olopatadine—Skin disorder—Estradiol—osteoporosis	0.000447	0.00105	CcSEcCtD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—IL6—osteoporosis	0.000446	0.00217	CbGpPWpGaD
Olopatadine—Rash—Ethinyl Estradiol—osteoporosis	0.000444	0.00105	CcSEcCtD
Olopatadine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000444	0.00104	CcSEcCtD
Olopatadine—Headache—Ethinyl Estradiol—osteoporosis	0.000441	0.00104	CcSEcCtD
Olopatadine—Hypersensitivity—Zoledronate—osteoporosis	0.00044	0.00103	CcSEcCtD
Olopatadine—Vomiting—Risedronate—osteoporosis	0.000437	0.00103	CcSEcCtD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—IL6—osteoporosis	0.000434	0.00211	CbGpPWpGaD
Olopatadine—Rash—Risedronate—osteoporosis	0.000433	0.00102	CcSEcCtD
Olopatadine—Dermatitis—Risedronate—osteoporosis	0.000433	0.00102	CcSEcCtD
Olopatadine—Dizziness—Pamidronate—osteoporosis	0.000432	0.00102	CcSEcCtD
Olopatadine—Headache—Risedronate—osteoporosis	0.00043	0.00101	CcSEcCtD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—IL6—osteoporosis	0.00043	0.0021	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—osteoporosis	0.00043	0.00209	CbGpPWpGaD
Olopatadine—Asthenia—Zoledronate—osteoporosis	0.000428	0.00101	CcSEcCtD
Olopatadine—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000427	0.00208	CbGpPWpGaD
Olopatadine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000423	0.000996	CcSEcCtD
Olopatadine—S100B—Immune System—IRAK3—osteoporosis	0.000423	0.00206	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—IL6—osteoporosis	0.000423	0.00206	CbGpPWpGaD
Olopatadine—Pruritus—Zoledronate—osteoporosis	0.000422	0.000993	CcSEcCtD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—IL6—osteoporosis	0.000422	0.00205	CbGpPWpGaD
Olopatadine—Nausea—Ethinyl Estradiol—osteoporosis	0.000419	0.000985	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—IRS1—osteoporosis	0.000416	0.00203	CbGpPWpGaD
Olopatadine—Vomiting—Pamidronate—osteoporosis	0.000415	0.000977	CcSEcCtD
Olopatadine—Asthenia—Conjugated Estrogens—osteoporosis	0.000412	0.00097	CcSEcCtD
Olopatadine—Rash—Pamidronate—osteoporosis	0.000412	0.000969	CcSEcCtD
Olopatadine—Dermatitis—Pamidronate—osteoporosis	0.000411	0.000968	CcSEcCtD
Olopatadine—Dyspnoea—Estradiol—osteoporosis	0.00041	0.000965	CcSEcCtD
Olopatadine—S100A12—Immune System—ACTG1—osteoporosis	0.000409	0.00199	CbGpPWpGaD
Olopatadine—Headache—Pamidronate—osteoporosis	0.000409	0.000963	CcSEcCtD
Olopatadine—Somnolence—Estradiol—osteoporosis	0.000409	0.000962	CcSEcCtD
Olopatadine—Diarrhoea—Zoledronate—osteoporosis	0.000408	0.000961	CcSEcCtD
Olopatadine—Nausea—Risedronate—osteoporosis	0.000408	0.00096	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—IL6—osteoporosis	0.000407	0.00198	CbGpPWpGaD
Olopatadine—Pruritus—Conjugated Estrogens—osteoporosis	0.000406	0.000956	CcSEcCtD
Olopatadine—S100A12—MyD88-independent cascade—IL6—osteoporosis	0.000406	0.00198	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTH1R—osteoporosis	0.000405	0.00197	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CALCR—osteoporosis	0.000405	0.00197	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—IL6—osteoporosis	0.0004	0.00195	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000397	0.000934	CcSEcCtD
Olopatadine—Fatigue—Estradiol—osteoporosis	0.000396	0.000933	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—KL—osteoporosis	0.000396	0.00193	CbGpPWpGaD
Olopatadine—Dizziness—Zoledronate—osteoporosis	0.000395	0.000928	CcSEcCtD
Olopatadine—Pain—Estradiol—osteoporosis	0.000393	0.000925	CcSEcCtD
Olopatadine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000393	0.000925	CcSEcCtD
Olopatadine—Nausea—Pamidronate—osteoporosis	0.000388	0.000913	CcSEcCtD
Olopatadine—S100B—Immune System—ACTG1—osteoporosis	0.000387	0.00188	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—IL6—osteoporosis	0.000384	0.00187	CbGpPWpGaD
Olopatadine—Dizziness—Conjugated Estrogens—osteoporosis	0.00038	0.000894	CcSEcCtD
Olopatadine—Vomiting—Zoledronate—osteoporosis	0.000379	0.000893	CcSEcCtD
Olopatadine—Feeling abnormal—Estradiol—osteoporosis	0.000379	0.000892	CcSEcCtD
Olopatadine—Rash—Zoledronate—osteoporosis	0.000376	0.000885	CcSEcCtD
Olopatadine—Gastrointestinal pain—Estradiol—osteoporosis	0.000376	0.000885	CcSEcCtD
Olopatadine—Dermatitis—Zoledronate—osteoporosis	0.000376	0.000884	CcSEcCtD
Olopatadine—S100B—Innate Immune System—KL—osteoporosis	0.000374	0.00182	CbGpPWpGaD
Olopatadine—Headache—Zoledronate—osteoporosis	0.000374	0.000879	CcSEcCtD
Olopatadine—HRH1—GPCR ligand binding—CALCR—osteoporosis	0.000373	0.00182	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—PTH1R—osteoporosis	0.000373	0.00182	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000367	0.00179	CbGpPWpGaD
Olopatadine—Vomiting—Conjugated Estrogens—osteoporosis	0.000365	0.000859	CcSEcCtD
Olopatadine—S100A12—Activated TLR4 signalling—IL6—osteoporosis	0.000365	0.00178	CbGpPWpGaD
Olopatadine—Body temperature increased—Estradiol—osteoporosis	0.000363	0.000855	CcSEcCtD
Olopatadine—Abdominal pain—Estradiol—osteoporosis	0.000363	0.000855	CcSEcCtD
Olopatadine—Rash—Conjugated Estrogens—osteoporosis	0.000362	0.000852	CcSEcCtD
Olopatadine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000362	0.000852	CcSEcCtD
Olopatadine—Headache—Conjugated Estrogens—osteoporosis	0.00036	0.000847	CcSEcCtD
Olopatadine—Nausea—Zoledronate—osteoporosis	0.000354	0.000834	CcSEcCtD
Olopatadine—S100B—Activated TLR4 signalling—IL6—osteoporosis	0.000345	0.00168	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—IL6—osteoporosis	0.000343	0.00167	CbGpPWpGaD
Olopatadine—S100A12—Immune System—RAP1A—osteoporosis	0.000342	0.00166	CbGpPWpGaD
Olopatadine—Nausea—Conjugated Estrogens—osteoporosis	0.000341	0.000803	CcSEcCtD
Olopatadine—S100A12—Immune System—CTSK—osteoporosis	0.000339	0.00165	CbGpPWpGaD
Olopatadine—Hypersensitivity—Estradiol—osteoporosis	0.000339	0.000797	CcSEcCtD
Olopatadine—S100A12—Immune System—NFATC1—osteoporosis	0.000334	0.00162	CbGpPWpGaD
Olopatadine—Asthenia—Estradiol—osteoporosis	0.00033	0.000776	CcSEcCtD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000328	0.0016	CbGpPWpGaD
Olopatadine—Pruritus—Estradiol—osteoporosis	0.000325	0.000765	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—IL6—osteoporosis	0.000325	0.00158	CbGpPWpGaD
Olopatadine—S100B—Immune System—RAP1A—osteoporosis	0.000323	0.00157	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MGLL—osteoporosis	0.000322	0.00157	CbGpPWpGaD
Olopatadine—S100B—Immune System—CTSK—osteoporosis	0.000321	0.00156	CbGpPWpGaD
Olopatadine—S100B—Immune System—NFATC1—osteoporosis	0.000315	0.00154	CbGpPWpGaD
Olopatadine—Diarrhoea—Estradiol—osteoporosis	0.000315	0.00074	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—LRP5—osteoporosis	0.000314	0.00153	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—AGER—osteoporosis	0.000311	0.00151	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—ADCY5—osteoporosis	0.00031	0.00151	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—IL6—osteoporosis	0.000306	0.00149	CbGpPWpGaD
Olopatadine—Dizziness—Estradiol—osteoporosis	0.000304	0.000715	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—LRP6—osteoporosis	0.0003	0.00146	CbGpPWpGaD
Olopatadine—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000294	0.00143	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—AGER—osteoporosis	0.000294	0.00143	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—ADCY5—osteoporosis	0.000293	0.00143	CbGpPWpGaD
Olopatadine—HRH1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000293	0.00142	CbGpPWpGaD
Olopatadine—Vomiting—Estradiol—osteoporosis	0.000292	0.000688	CcSEcCtD
Olopatadine—Rash—Estradiol—osteoporosis	0.00029	0.000682	CcSEcCtD
Olopatadine—Dermatitis—Estradiol—osteoporosis	0.00029	0.000682	CcSEcCtD
Olopatadine—S100B—Toll-Like Receptors Cascades—IL6—osteoporosis	0.000289	0.00141	CbGpPWpGaD
Olopatadine—Headache—Estradiol—osteoporosis	0.000288	0.000678	CcSEcCtD
Olopatadine—Nausea—Estradiol—osteoporosis	0.000273	0.000643	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—IL6—osteoporosis	0.000272	0.00133	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PSMA2—osteoporosis	0.000272	0.00133	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PSMA5—osteoporosis	0.000272	0.00133	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IRS2—osteoporosis	0.000271	0.00132	CbGpPWpGaD
Olopatadine—S100B—Immune System—PSMA2—osteoporosis	0.000258	0.00125	CbGpPWpGaD
Olopatadine—S100B—Immune System—PSMA5—osteoporosis	0.000258	0.00125	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IRS2—osteoporosis	0.000256	0.00125	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TLN1—osteoporosis	0.000254	0.00123	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000251	0.00122	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000238	0.00116	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IRS1—osteoporosis	0.000237	0.00115	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000235	0.00114	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KL—osteoporosis	0.00023	0.00112	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IRS1—osteoporosis	0.000224	0.00109	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IL6R—osteoporosis	0.000222	0.00108	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—P4HB—osteoporosis	0.000219	0.00106	CbGpPWpGaD
Olopatadine—S100B—Immune System—KL—osteoporosis	0.000218	0.00106	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTH—osteoporosis	0.000213	0.00104	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PTH1R—osteoporosis	0.000211	0.00103	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CALCR—osteoporosis	0.000211	0.00103	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IL6R—osteoporosis	0.00021	0.00102	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—RAP1A—osteoporosis	0.000209	0.00102	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CNR2—osteoporosis	0.000207	0.00101	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NFATC1—osteoporosis	0.000204	0.000993	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—DKK1—osteoporosis	0.000202	0.000985	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—PTH—osteoporosis	0.000196	0.000954	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000195	0.00095	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—WNT1—osteoporosis	0.000195	0.000949	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000193	0.000939	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000192	0.000937	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PTH1R—osteoporosis	0.000191	0.000932	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CALCR—osteoporosis	0.000191	0.000932	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CNR2—osteoporosis	0.000191	0.00093	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FGA—osteoporosis	0.00019	0.000923	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AGER—osteoporosis	0.000181	0.000882	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ADCY5—osteoporosis	0.000181	0.000879	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—WNT1—osteoporosis	0.00018	0.000874	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—BMP2—osteoporosis	0.000176	0.000858	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTHLH—osteoporosis	0.000176	0.000858	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FGB—osteoporosis	0.000172	0.00084	CbGpPWpGaD
Olopatadine—S100B—Immune System—AGER—osteoporosis	0.000171	0.000834	CbGpPWpGaD
Olopatadine—S100B—Immune System—ADCY5—osteoporosis	0.000171	0.000831	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—MGLL—osteoporosis	0.000167	0.000815	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PSMA2—osteoporosis	0.000167	0.000811	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PSMA5—osteoporosis	0.000167	0.000811	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—PTHLH—osteoporosis	0.000162	0.00079	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IRS2—osteoporosis	0.000158	0.000769	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CALCA—osteoporosis	0.000155	0.000755	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MGLL—osteoporosis	0.000152	0.00074	CbGpPWpGaD
Olopatadine—S100B—Immune System—IRS2—osteoporosis	0.000149	0.000727	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000143	0.000696	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CALCA—osteoporosis	0.000143	0.000696	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KL—osteoporosis	0.000141	0.000686	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IRS1—osteoporosis	0.000138	0.000671	CbGpPWpGaD
Olopatadine—S100B—Immune System—IRS1—osteoporosis	0.00013	0.000635	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6R—osteoporosis	0.00013	0.000631	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000129	0.00063	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SOST—osteoporosis	0.000125	0.000609	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6R—osteoporosis	0.000123	0.000596	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000116	0.000564	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CALCR—osteoporosis	0.000113	0.000551	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTH1R—osteoporosis	0.000113	0.000551	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PTH—osteoporosis	0.000111	0.000539	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ADCY5—osteoporosis	0.00011	0.000537	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CNR2—osteoporosis	0.000108	0.000525	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SPP1—osteoporosis	0.000107	0.00052	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	0.000102	0.000499	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	0.000101	0.000492	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PTH—osteoporosis	0.000101	0.00049	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IL6—osteoporosis	9.91e-05	0.000482	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL1B—osteoporosis	9.85e-05	0.00048	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	9.82e-05	0.000478	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CNR2—osteoporosis	9.8e-05	0.000477	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IRS2—osteoporosis	9.66e-05	0.00047	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—LEP—osteoporosis	9.45e-05	0.00046	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IL6—osteoporosis	9.37e-05	0.000456	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL1B—osteoporosis	9.32e-05	0.000454	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—WNT1—osteoporosis	9.21e-05	0.000449	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PTHLH—osteoporosis	9.18e-05	0.000447	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ESR1—osteoporosis	9.02e-05	0.000439	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MGLL—osteoporosis	8.98e-05	0.000437	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LRP5—osteoporosis	8.77e-05	0.000427	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IRS1—osteoporosis	8.43e-05	0.00041	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LRP6—osteoporosis	8.39e-05	0.000408	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PTHLH—osteoporosis	8.33e-05	0.000406	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—POMC—osteoporosis	8.12e-05	0.000395	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CALCA—osteoporosis	8.08e-05	0.000393	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6R—osteoporosis	7.92e-05	0.000386	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IGF1—osteoporosis	7.81e-05	0.00038	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—POMC—osteoporosis	7.48e-05	0.000364	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CALCA—osteoporosis	7.34e-05	0.000357	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TLN1—osteoporosis	7.08e-05	0.000345	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—POMC—osteoporosis	6.16e-05	0.0003	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—P4HB—osteoporosis	6.11e-05	0.000297	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTH—osteoporosis	5.94e-05	0.000289	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RAP1A—osteoporosis	5.84e-05	0.000284	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PKM—osteoporosis	5.81e-05	0.000283	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—FDPS—osteoporosis	5.81e-05	0.000283	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CNR2—osteoporosis	5.79e-05	0.000282	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6—osteoporosis	5.77e-05	0.000281	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	5.76e-05	0.000281	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—ADCY5—osteoporosis	5.75e-05	0.00028	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NFATC1—osteoporosis	5.7e-05	0.000277	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—DKK1—osteoporosis	5.65e-05	0.000275	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GPD2—osteoporosis	5.51e-05	0.000268	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PGLS—osteoporosis	5.51e-05	0.000268	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6—osteoporosis	5.46e-05	0.000266	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—WNT1—osteoporosis	5.44e-05	0.000265	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGA—osteoporosis	5.3e-05	0.000258	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—ADCY5—osteoporosis	5.22e-05	0.000254	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ATIC—osteoporosis	5.04e-05	0.000245	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PNP—osteoporosis	5.04e-05	0.000245	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTHLH—osteoporosis	4.92e-05	0.00024	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—BMP2—osteoporosis	4.92e-05	0.00024	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGB—osteoporosis	4.82e-05	0.000235	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—osteoporosis	4.69e-05	0.000228	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TGFB1—osteoporosis	4.68e-05	0.000228	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PSMA2—osteoporosis	4.65e-05	0.000226	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PSMA5—osteoporosis	4.65e-05	0.000226	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CALCA—osteoporosis	4.33e-05	0.000211	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—OXCT1—osteoporosis	4.28e-05	0.000208	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CA2—osteoporosis	4.28e-05	0.000208	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—POMC—osteoporosis	4.23e-05	0.000206	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MGLL—osteoporosis	4.17e-05	0.000203	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KL—osteoporosis	3.94e-05	0.000192	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—POMC—osteoporosis	3.84e-05	0.000187	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6R—osteoporosis	3.74e-05	0.000182	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—IDH2—osteoporosis	3.55e-05	0.000173	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6—osteoporosis	3.53e-05	0.000172	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.34e-05	0.000162	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ACP5—osteoporosis	3.25e-05	0.000158	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ADCY5—osteoporosis	3.08e-05	0.00015	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TPI1—osteoporosis	3.02e-05	0.000147	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SPP1—osteoporosis	2.98e-05	0.000145	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—P4HB—osteoporosis	2.84e-05	0.000138	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GAPDH—osteoporosis	2.78e-05	0.000136	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—RAP1A—osteoporosis	2.71e-05	0.000132	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IRS2—osteoporosis	2.7e-05	0.000131	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LEP—osteoporosis	2.64e-05	0.000128	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—osteoporosis	2.52e-05	0.000123	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IRS1—osteoporosis	2.35e-05	0.000115	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—POMC—osteoporosis	2.27e-05	0.00011	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6R—osteoporosis	2.21e-05	0.000108	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ENO1—osteoporosis	2.19e-05	0.000107	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF1—osteoporosis	2.18e-05	0.000106	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PSMA2—osteoporosis	2.16e-05	0.000105	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PSMA5—osteoporosis	2.16e-05	0.000105	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.75e-05	8.53e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6—osteoporosis	1.67e-05	8.12e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ADCY5—osteoporosis	1.43e-05	6.97e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GPX1—osteoporosis	1.43e-05	6.95e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTHFR—osteoporosis	1.32e-05	6.41e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—osteoporosis	1.31e-05	6.38e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFB1—osteoporosis	1.31e-05	6.37e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—POMC—osteoporosis	1.05e-05	5.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6—osteoporosis	9.85e-06	4.8e-05	CbGpPWpGaD
